$4.66
0.65% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US8106481059
Symbol
SCPH

scPharmaceuticals, Inc. Stock price

$4.66
+0.28 6.39% 1M
+1.32 39.52% 6M
+1.12 31.64% YTD
+0.23 5.19% 1Y
-1.22 20.75% 3Y
-3.69 44.19% 5Y
-9.44 66.95% 10Y
-9.44 66.95% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.03 0.65%
ISIN
US8106481059
Symbol
SCPH
Industry

Key metrics

Basic
Market capitalization
$244.4m
Enterprise Value
$237.9m
Net debt
positive
Cash
$57.5m
Shares outstanding
50.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.8 | 3.2
EV/Sales
5.7 | 3.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
12.4%
Return on Equity
-639.3%
ROCE
-106.8%
ROIC
-
Debt/Equity
-10.0
Financials (TTM | estimate)
Revenue
$42.0m | $75.9m
EBITDA
$-79.6m | $-48.6m
EBIT
$-79.7m | $-53.7m
Net Income
$-90.8m | $-53.6m
Free Cash Flow
$-70.0m
Growth (TTM | estimate)
Revenue
138.0% | 109.0%
EBITDA
-33.4% | 24.9%
EBIT
-33.5% | 17.1%
Net Income
-57.3% | 37.1%
Free Cash Flow
-15.8%
Margin (TTM | estimate)
Gross
68.9%
EBITDA
-189.5% | -64.0%
EBIT
-189.9%
Net
-216.2% | -70.6%
Free Cash Flow
-166.7%
More
EPS
$-1.7
FCF per Share
$-1.4
Short interest
3.4%
Employees
163
Rev per Employee
$220.0k
Show more

Is scPharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

scPharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a scPharmaceuticals, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a scPharmaceuticals, Inc. forecast:

Buy
91%
Hold
9%

Financial data from scPharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
42 42
138% 138%
100%
- Direct Costs 13 13
162% 162%
31%
29 29
129% 129%
69%
- Selling and Administrative Expenses 82 82
36% 36%
194%
- Research and Development Expense 14 14
13% 13%
33%
-80 -80
33% 33%
-189%
- Depreciation and Amortization 0.16 0.16
129% 129%
0%
EBIT (Operating Income) EBIT -80 -80
34% 34%
-190%
Net Profit -91 -91
57% 57%
-216%

In millions USD.

Don't miss a Thing! We will send you all news about scPharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

scPharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John Mohr - Senior Vice President of Clinical Development & Medical Affairs John H. Tucker - President, CEO, Principal Executive Officer & Director Rachael Nokes - Chief Financial Officer Steve C.
Neutral
The Motley Fool
4 days ago
SCPH Revenue Up 99%
Neutral
GlobeNewsWire
4 days ago
Generated net FUROSCIX ® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024
More scPharmaceuticals, Inc. News

Company Profile

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Head office United States
CEO John Tucker
Employees 163
Founded 2013
Website www.scpharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today